Can Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more
Can Fite Biopharma Ltd - Asset Resilience Ratio
Can Fite Biopharma Ltd (CANF) has an Asset Resilience Ratio of 0.03% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Can Fite Biopharma Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Can Fite Biopharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA2.00K | 0.03% |
| Total Liquid Assets | ILA2.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Can Fite Biopharma Ltd maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Can Fite Biopharma Ltd Industry Peers by Asset Resilience Ratio
Compare Can Fite Biopharma Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF |
Biotechnology | 25.67% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Exicure Inc
NASDAQ:XCUR |
Biotechnology | 0.00% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Can Fite Biopharma Ltd (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Can Fite Biopharma Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 33.57% | ILA3.06 Million | ILA9.12 Million | -12.92pp |
| 2023-12-31 | 46.49% | ILA4.64 Million | ILA9.99 Million | -7.38pp |
| 2022-12-31 | 53.87% | ILA5.00 Million | ILA9.28 Million | -18.95pp |
| 2021-12-31 | 72.82% | ILA14.75 Million | ILA20.25 Million | +72.04pp |
| 2020-12-31 | 0.79% | ILA75.00K | ILA9.52 Million | +0.00pp |
| 2019-12-31 | 0.78% | ILA64.00K | ILA8.17 Million | -2.65pp |
| 2018-12-31 | 3.43% | ILA273.00K | ILA7.95 Million | -63.80pp |
| 2006-12-31 | 67.23% | ILA28.08 Million | ILA41.76 Million | -- |